News & Events · January 27, 2022 Yamo Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study of L1-79 in Autism Spectrum Disorder https://www.globenewswire.com/news-release/2022/01/27/2374277/0/en/Yamo-Pharmaceuticals-Announces-Enrollment-of-First-Patient-in-Phase-2-Study-of-L1-79-in-Autism-Spectrum-Disorder.html
News & Events · November 10, 2021 Yamo Pharmaceuticals Receives Investment from Autism Impact Fund to Support Phase 2 Study of L1-79 in Autism Spectrum Disorder https://www.globenewswire.com/news-release/2021/11/10/2331897/0/en/Yamo-Pharmaceuticals-Receives-Investment-from-Autism-Impact-Fund-to-Support-Phase-2-Study-of-L1-79-in-Autism-Spectrum-Disorder.html
News & Events · November 10, 2021 The Autism Impact Fund Makes First Investments in Seven Early-stage Companies https://www.prnewswire.com/news-releases/the-autism-impact-fund-makes-first-investments-in-seven-early-stage-companies-301421062.html
